CytoMed Therapeutics Limited (GDTC)

CytoMed Therapeutics Income Statement

Financials in millions SGD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	0.23	0.07	-	-	-	-
Other Revenue	0.5	0.43	0.51	0.36	0.11	0.06
Revenue	0.73	0.5	0.51	0.36	0.11	0.06
Revenue Growth (YoY)	63.03%	-0.86%	39.52%	219.67%	91.43%	-
Cost of Revenue	0.05	0.03	0	0.01	0	0
Gross Profit	0.68	0.47	0.5	0.36	0.11	0.05
Selling, General & Admin	0.74	0.65	0.49	0.21	0.17	0.14
Research & Development	2.1	1.91	1.59	1.52	1.09	1.04
Other Operating Expenses	0.83	0.92	2.16	0.37	0.49	0.11
Operating Expenses	4.2	3.6	4.35	2.21	1.85	1.37
Operating Income	-3.52	-3.13	-3.84	-1.86	-1.74	-1.32
Interest Expense	-0.02	-0.02	-0.05	-0.13	-0.12	-0.11
Interest & Investment Income	0.21	0.32	0.29	0	0	-
Earnings From Equity Investments	-0.01	0.01	-0.03	-0.03	-0.21	-
Currency Exchange Gain (Loss)	-0.24	0.16	-0.17	-0.03	-0.01	-0
Other Non Operating Income (Expenses)	-0.09	0.14	-0.22	-	-	-
EBT Excluding Unusual Items	-3.67	-2.52	-4.03	-2.04	-2.08	-1.42
Gain (Loss) on Sale of Assets	-0	-	-	0	-	-
Other Unusual Items	-	-	-0.1	-1.09	0.02	-0.51
Pretax Income	-3.68	-2.52	-4.13	-3.13	-2.05	-1.94
Income Tax Expense	-	-	0	0	-	-
Earnings From Continuing Operations	-3.68	-2.52	-4.13	-3.13	-2.05	-1.94
Minority Interest in Earnings	0.01	0.01	0	0	0	0
Net Income	-3.67	-2.52	-4.13	-3.13	-2.05	-1.94
Net Income to Common	-3.67	-2.52	-4.13	-3.13	-2.05	-1.94
Shares Outstanding (Basic)	12	12	11	8	7	6
Shares Outstanding (Diluted)	12	12	11	8	7	6
Shares Change (YoY)	-	8.56%	34.30%	14.14%	17.59%	6.22%
EPS (Basic)	-0.32	-0.22	-0.39	-0.40	-0.30	-0.33
EPS (Diluted)	-0.32	-0.22	-0.39	-0.40	-0.30	-0.33
Free Cash Flow	-3.99	-4.11	-3.59	-1.87	-2.3	-1.09
Free Cash Flow Per Share	-0.35	-0.36	-0.34	-0.24	-0.33	-0.19
Gross Margin	92.52%	93.83%	99.27%	97.60%	96.92%	92.22%
Operating Margin	-482.59%	-621.91%	-756.86%	-511.02%	-1528.84%	-2215.85%
Profit Margin	-503.11%	-499.97%	-813.98%	-860.43%	-1802.21%	-3254.59%
Free Cash Flow Margin	-546.82%	-816.52%	-706.96%	-514.47%	-2016.27%	-1839.93%
EBITDA	-3.18	-2.8	-3.46	-1.47	-1.41	-1.03
D&A For EBITDA	0.34	0.33	0.38	0.39	0.33	0.29
EBIT	-3.52	-3.13	-3.84	-1.86	-1.74	-1.32
Advertising Expenses	-	0.02	0.03	-	0	0.01

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q